These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Retreatment interval lengthening achieved in two thirds of eyes with prolonged intensive anti-VEGF therapy for neovascular age-related macular degeneration after switching to faricimab. Kenworthy MK; Alexis JA; Ramakrishnan P; Chen FK Clin Exp Ophthalmol; 2024 Jul; 52(5):589-591. PubMed ID: 38069616 [No Abstract] [Full Text] [Related]
3. A Mechanistic Model of the Intravitreal Pharmacokinetics of Large Molecules and the Pharmacodynamic Suppression of Ocular Vascular Endothelial Growth Factor Levels by Ranibizumab in Patients with Neovascular Age-Related Macular Degeneration. Hutton-Smith LA; Gaffney EA; Byrne HM; Maini PK; Schwab D; Mazer NA Mol Pharm; 2016 Sep; 13(9):2941-50. PubMed ID: 26726925 [TBL] [Abstract][Full Text] [Related]
5. Intravitreal ranibizumab injection for neovascular age-related macular degeneration in phakic versus pseudophakic eyes. Baek JS; Cho HJ; Cho SW; Kim CG; Kim JW Retina; 2013 Mar; 33(3):467-73. PubMed ID: 23400082 [TBL] [Abstract][Full Text] [Related]
6. EFFICACY OF ADJUVANT TOPICAL DORZOLAMIDE-TIMOLOL IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION REFRACTORY TO ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY. Lee JH; Lee SC; Byeon SH; Koh HJ; Kim SS; Lee CS Retina; 2019 Oct; 39(10):1953-1958. PubMed ID: 30161096 [TBL] [Abstract][Full Text] [Related]
7. Innovation in Neovascular Age-Related Macular Degeneration: Consideration of Brolucizumab, Abicipar, and the Port Delivery System. Wykoff CC; Hariprasad SM; Zhou B Ophthalmic Surg Lasers Imaging Retina; 2018 Dec; 49(12):913-917. PubMed ID: 30566697 [No Abstract] [Full Text] [Related]